Palisade Bio Inc. [NASDAQ: PALI] plunged by -$0.84 during the normal trading session on Friday and reaching a high of $4.37 during the day while it closed the day at $3.76. The company report on May 13, 2021 that Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery.
LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery.
A Phase 2 gastrointestinal surgery trial that will evaluate LB1148 for reduction in adhesions is expected to read out data in 2021.
Palisade Bio Inc. stock has also loss -37.02% of its value over the past 7 days. However, PALI stock has declined by -65.94% in the 3 months of the year. Over the past six months meanwhile, it has gained 10.23% and lost -28.79% year-on date.
The market cap for PALI stock reached $33.69 million, with 2.89 million shares outstanding and 2.86 million shares in the current float. Compared to the average trading volume of 1.18M shares, PALI reached a trading volume of 2740129 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Palisade Bio Inc. [PALI]:
The Average True Range (ATR) for Palisade Bio Inc. is set at 1.10 The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 1.17.
PALI stock trade performance evaluation
Palisade Bio Inc. [PALI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -37.02. With this latest performance, PALI shares dropped by -55.87% in over the last four-week period, additionally plugging by 10.23% over the last 6 months – not to mention a drop of -16.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PALI stock in for the last two-week period is set at 23.68, with the RSI for the last a single of trading hit 15.58, and the three-weeks RSI is set at 30.01 for Palisade Bio Inc. [PALI]. The present Moving Average for the last 50 days of trading for this stock 8.66, while it was recorded at 4.86 for the last single week of trading, and 6.19 for the last 200 days.
Palisade Bio Inc. [PALI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Palisade Bio Inc. [PALI] shares currently have an operating margin of -78961.14. Palisade Bio Inc.’s Net Margin is presently recorded at -120316.72.
Return on Total Capital for PALI is now -141.63, given the latest momentum, and Return on Invested Capital for the company is -216.28. Return on Equity for this stock declined to -218.44, with Return on Assets sitting at -165.71.
Reflecting on the efficiency of the workforce at the company, Palisade Bio Inc. [PALI] managed to generate an average of -$2,323,831 per employee. Receivables Turnover for the company is 0.20 with a Total Asset Turnover recorded at a value of 0.00.Palisade Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.00.
Palisade Bio Inc. [PALI]: Insider Ownership positions
There are presently around $1 million, or 5.40% of PALI stock, in the hands of institutional investors. The top three institutional holders of PALI stocks are: VANGUARD GROUP INC with ownership of 61,071, which is approximately 896.264% of the company’s market cap and around 0.32% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 20,593 shares of the stock with an approximate value of $77000.0 in PALI stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $75000.0 in PALI stock with ownership of nearly New of the company’s market capitalization.
Positions in Palisade Bio Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 8 institutional holders increased their position in Palisade Bio Inc. [NASDAQ:PALI] by around 96,889 shares. Additionally, 3 investors decreased positions by around 94,020 shares, while 12 investors held positions by with 49,670 shares. The mentioned changes placed institutional holdings at 141,239 shares, according to the latest SEC report filing. PALI stock had 4 new institutional investments in for a total of 21,579 shares, while 2 institutional investors sold positions of 93,489 shares during the same period.